Comparison · NCT00517933-56f65bed
Sildenafil vs Placebo: Change in 6-minute Walk Distance From Enrollment to Week 12 (≥ 20% Improvement)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sildenafil vs Placebo: Change in 6-minute Walk Distance From Enrollment to Week 12 (≥ 20% Improvement). Trial comparisons, record NCT00517933-56f65bed. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00517933-56f65bed
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.101 | 0.0541 | 0.181 | wilson | |
| Risk in group 2 | 0.0659 | 0.0306 | 0.136 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0352 | -0.0496 | 0.123 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.53 | 0.569 | 4.13 | log | |
| Odds ratio, group 1 over group 2 | 1.59 | 0.543 | 4.68 | log | |
| Number needed to treat, for one more participant with the outcome on Sildenafil than on Placebo | 28.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sildenafil | 20 mg of oral sildenafil 3 times per day for 12 weeks, followed by 20 mg oral sildenafil 3 times per day for an additional 12 weeks. | 9 | 89 | OG000 |
| Group 2 | Placebo | 20 mg of placebo 3 times per day for 12 weeks, followed by 20 mg open-label sildenafil 3 times per day for 12 weeks | 6 | 91 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Change in 6-minute Walk Distance From Enrollment to Week 12 (≥ 20% Improvement)
- Description
This is a binary score (1 or 0) with 1 being better than 0. All models adjust for baseline values of age, height, sex, white race, and DLCO. Values from models are estimated changes from baseline to 12 weeks (with 95% confidence intervals). The difference estimate is based on sildenafil - placebo.
- Time frame
- Measured at Week 12
- Population
Source ClinicalTrials.gov
Trial
- Title
- Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
- NCT number
- NCT00517933
- Phases
- PHASE3
- Conditions
- Pulmonary Fibrosis, Hypertension, Pulmonary
- Interventions
- Sildenafil Citrate, Placebo
- Lead sponsor
- Duke University
- Results first posted
- 2013-08-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00517933?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00517933-56f65bed